Ignite Creation Date:
2024-05-06 @ 6:59 PM
Last Modification Date:
2024-10-26 @ 2:58 PM
Study NCT ID:
NCT05853900
Status:
COMPLETED
Last Update Posted:
2024-05-31
First Post:
2023-04-18
Brief Title:
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine
Sponsor:
Click Therapeutics Inc
Organization:
Click Therapeutics Inc
Study Overview
Official Title:
A Randomized Double-blind Parallel-Group Virtual Study to Evaluate the Efficacy and Safety of Two Digital Therapeutics in Late Adolescents and Adults for the Prevention of Episodic Migraine
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ReMMi-D
Brief Summary:
Randomized study of two digital therapeutics for the prevention of episodic migraine
Detailed Description:
The purpose of this randomized ReMMi-D trial is to evaluate the efficacy and safety of two prescription mobile applications that provide an interactive software-based intervention for the preventative treatment of episodic migraine in late adolescents and adults
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
True
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None